Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market dynamics of transient ischemic attack (TIA), also known as a mini-stroke, are influenced by various factors that impact the diagnosis, treatment, and prevention of this condition. A TIA occurs when blood flow to the brain is temporarily disrupted, often resulting in symptoms similar to those of a stroke, such as weakness, numbness, or difficulty speaking. Despite being temporary, TIAs are warning signs of potential future strokes, making early detection and management crucial.
One of the key drivers of the TIA market is the increasing prevalence of risk factors such as hypertension, diabetes, and obesity. As these risk factors become more prevalent globally, the incidence of TIAs is expected to rise, driving demand for diagnostic tools and treatment options. Moreover, aging populations in many countries contribute to the growing burden of cerebrovascular diseases, including TIAs, further fueling market growth.
Advancements in medical imaging and diagnostic technologies have revolutionized the detection and characterization of TIAs. Imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound play a crucial role in diagnosing TIAs and identifying underlying causes such as carotid artery disease or atrial fibrillation. Additionally, point-of-care diagnostic tests enable rapid assessment of patients presenting with TIA symptoms, facilitating prompt treatment and management.
The treatment landscape for TIAs encompasses various therapeutic approaches aimed at preventing recurrent strokes and managing underlying risk factors. Antiplatelet medications such as aspirin and clopidogrel are commonly prescribed to reduce the risk of blood clot formation and subsequent stroke following a TIA. Furthermore, interventions such as carotid endarterectomy or stenting may be recommended to address significant carotid artery stenosis, a common cause of TIAs. Additionally, lifestyle modifications including smoking cessation, dietary changes, and exercise are integral components of TIA management and prevention.
Healthcare policies and reimbursement frameworks also influence the market dynamics of TIAs. Access to timely diagnosis, treatment, and follow-up care is essential for optimizing patient outcomes and reducing the risk of recurrent strokes. Reimbursement policies for diagnostic tests, medications, and procedures vary across different healthcare systems, impacting market access and adoption of TIA management strategies. Moreover, initiatives aimed at raising awareness about TIAs and promoting preventive measures contribute to market dynamics by driving demand for screening programs and educational resources.
Collaboration among stakeholders in the healthcare ecosystem is essential for addressing the multifaceted challenges associated with TIAs. Healthcare providers, including neurologists, primary care physicians, and emergency department personnel, play a critical role in identifying and managing patients with TIAs. Additionally, partnerships between healthcare organizations, research institutions, and pharmaceutical companies drive innovation in TIA diagnostics and therapeutics, leading to improved patient outcomes.
Market dynamics in the TIA space are also influenced by regulatory considerations and technological advancements. Regulatory agencies such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe oversee the approval and marketing of medical devices, pharmaceuticals, and interventions for TIA management. Stringent regulatory standards ensure the safety, efficacy, and quality of TIA treatments while also shaping market entry and competition.
Technological innovations continue to drive progress in TIA management, with ongoing research focused on novel diagnostic biomarkers, targeted therapies, and non-invasive treatment modalities. Advances in telemedicine and digital health technologies enable remote monitoring of patients with TIAs, facilitating timely intervention and follow-up care. Furthermore, artificial intelligence and machine learning algorithms hold promise for enhancing risk stratification and personalized treatment approaches for individuals at high risk of recurrent strokes.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|
Transient Ischemic Attack Market Highlights:
Transient Ischemic Attack Market Overview
The transient ischemic attack market is anticipated to reach USD 2026.6 Million by 2030 at 5.70% CAGR during the forecast period 2022-2030
Transient ischemic stroke is also known as a mini-stroke. It leads to temporary blockage of blood flow to the brain. As it does not cause permanent damage, it is often ignored. The market is mainly driven by factors such as the rising prevalence of ischemia stroke cases, growing geriatric population, and increasing healthcare expenditure. However, the high cost of surgical procedures for the treatment of ischemic is likely to hinder the market growth.
Market Dynamics
The transient ischemic attack market is expected to exhibit exponential growth during the forecast period which is driven by all-rounder characteristics of the transient ischemic attack, increasing prevalence of chronic diseases such as cardiovascular diseases and cancer, and increase in the treatment of chronic diseases for the elderly population. It has been identified as one of the fastest emerging industries owing to the changing dynamics of the legal and regulatory framework and the intense competitive rivalry among an excess of public companies. As per the survey carried out by American Heart Association Report 2015, more than 17.9 million deaths were recorded in the US due to cardiovascular disorder, and the death rate is expected to grow to more than 23.6 Million by 2030. Besides, increasing healthcare expenditure has fueled the growth of the market. However, the growth of the market is restrained by the side effects of drugs for strokes and strict regulations for manufacturing medical devices for the treatment of strokes.
Transient Ischemic Attack Market Size, by Diagnosis, 2016 and 2023 (USD Million) Â 
Source: MRFR Analysis
Segmentation
The transient ischemic attack has been segmented into diagnosis, treatment, age group, and end user. Based on the diagnosis, the market has been divided into imaging techniques and others. The imaging technique is further sub-segmented into computed tomography (CT) scan, carotid duplex scanning, magnetic resonance imaging, and echocardiography. The imaging technique segment accounted for a market value of USD 1004.4 Million in 2016. Based on treatment, the market has been segregated into surgery and drugs. The drugs segment is further sub-segmented into antithrombotic agents, antiplatelets, clopidogrel, aspirin, heparins, enoxaparin, dalteparin, fibrinolytic, and tenecteplase. By age groups, the market is further classified as  0–18 years, 19–40 years (Millennial), 41–60 years, and 60+ years. Based on end-user, the transient ischemic attack market has been bifurcated into hospitals & clinics, diagnostic centers, and research laboratories.
Key Players
The prominent players in the transient ischemic attack market are Koninklijke Philips NV (Netherlands), Stryker Corporation (US), Johnson & Johnson Services Inc (US), Boston Scientific Corporation (US), Sanofi (France), Bayer AG (Germany), Pfizer Inc (US), Siemens AG (US), F. Hoffmann-La Roche AG (Switzerland), GE Healthcare (UK), Penumbra Inc (California), Medtronic PLC (Ireland), Abbott Laboratories (US), Merck & Co., Inc (US), and Boehringer Ingelheim GmbH (Germany).Â
Some of the key strategies followed by the players operating in the transient ischemic attack market were innovation, product development, acquisition, mergers, and expansion.
 Asia-Pacific Transient Ischemic Attack Market Share, By Country, 2016 (%)  
Source: MRFR Analysis
Regional Analysis
The transient ischemic attack market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is estimated to dominate the transient ischemic attack market during the forecast period. This is attributed due to the well-developed technology, rising healthcare expenditure, and the presence of the leading players in the market. People in this region are very health conscious, which has led to increasing healthcare expenditure in this region.
Europe accounted for the second-largest market for transient ischemic attack. Rising investment in research & development, well-developed healthcare infrastructure, and increasing healthcare funds are some of the factors responsible for boosting the growth of the market in this region.
Asia-Pacific is projected to be the fastest-growing market due to the rising aging population, increasing healthcare expenditure, and the rising prevalence of cardiac disorders. In addition to this, improving healthcare facilities and rising economic growth is positively impacting the market growth in this region. Japan held the most significant market share of 32.97 % in 2016.
The market in the Middle East & Africa is expected to witness steady growth due to increasing investments in research & development, well-developed infrastructure, and advancement in technology.
Key Updates
-
In February 2018, Merck & Co. Inc acquired Viralytics Limited. This acquisition expanded Merck’s immunology pipeline.
-
In January 2018, Abbott entered into a definitive merger agreement by acquiring Alere Inc., a diagnostic device and service provider, for USD 56.00 per common share in cash.
-
In October 2018, Stryker Corporation announced the acquisition of VEXIM, a French medical device company. This acquisition enabled Stryker Corporation to increase its revenue in the future.
-
In August 2017, Sanofi completed the acquisition of Protein Sciences. This acquisition was a strategic fit for Sanofi Pasteur’s for developing new manufacturing technologies.
-
In May 2017, Boston Scientific Corporation announced the acquisition of Symetis SA, to focus on minimally invasive transcatheter aortic valve implantation (TAVI) devices.
Market Segmentation
Transient Ischemic Attack Market, by Diagnosis
- Imaging Techniques
- Computed Tomography (CT) scan
- Carotid Duplex Scanning
- Magnetic Resonance Imaging
- Echocardiography      Â
Transient Ischemic Attack Market, by Treatment
- Surgery
- Drugs
- Antithrombotic agents
- Antiplatelets
- Clopidogrel
- Aspirin
- Heparins
- ENOXAPARIN
- DALTEPARIN
- Fibrinolytics
- Tenecteplase
Transient Ischemic Attack Market, by Age Groups
- 0–18 years
- 19–40 years (Millennial)
- 41–60 years
- 60+ years
Transient Ischemic Attack Market, by End-User
- Hospitals & Clinics
- Diagnostic Centers
- Research Laboratories
Transient Ischemic Attack Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Available Additional Customizations
- Additional Companies
- LivaNova PLC
- EnteroMedics Inc.
- ElectroCore Medical LLC
- Cyberonics, Inc.
- NeuroMetrix, Inc.
- ImThera Medical
- Inspire Medical Systems, Inc.
- Nihon Kohden Corporation
- Electrical Geodesics Inc.
Intended Audience
- Medical device manufacturers and distributors
- Government research organizations
- Hospitals and clinics
- Regulatory agencies
-
Contract research organizations - Academic institutes and universities
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
